Shares of Cerevel Therapeutics (NASDAQ: CERE) a pharma company shot up by more than 20% in morning trading on Monday after it announced the results of a randomized, double-blind Phase 1 trial. This trial studied the effect of emraclidine on ambulatory blood pressure over a duration of 24 hours over an eight-week period in people living with schizophrenia.
This trial indicated that emraclidine did not increase blood pressure.
CERE scores a Strong Buy consensus rating from Wall Street analysts based on six Buys and two Holds.
